K.HeilmannC
The most significant clinical data for retatrutide to date comes from a Phase 2 randomised controlled trial published in The New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023)
Compared to usual care, GLP-1RA use was associated with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions
Pure Encapsulations also takes transparency a bit further: While it lists its proprietary glutathione complex BioGlute on the ingredient label, it breaks down exactly what is in it250 mg of Setria l-glutathione and 125 mg of a phospholipid complexfor total clarity
If nausea is frequent, bland foods and slower eating may be easier to tolerate
Common adverse effects include gastrointestinal symptomsnausea, vomiting, diarrhea, and constipationwhich typically diminish with continued use
